Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of CVL218 in BRCA-mutated metastatic castration-resistant prostate cancer
CTR20211367Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mefuparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Institute of Materia Medica. Started Jun 2021; status: active.
02
Drugs
mefuparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20211367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211367.